论文部分内容阅读
作者于1969～1970年在缅甸进行了抗氯喹恶性疟的临床验证。试验对象均为现症病人,试验方法和抗性分级均按世界卫生组织规定。试验病例均作尿中氯喹测定,部分病例测定血浆中氯喹浓度。共调查了105例,RI 66例,RⅡ19例,RⅢ3例,敏感者17例。凡查出的抗氯喹病例就随机分成10个组,各投以不同药物或复方治疗,如仍无效,最后给以奎宁治疗。试验发现,抗氯喹病例中对其他某些药物或复方也有不同程度的耐受性:乙胺嘧啶50毫克单次治疗6例,均在7～28天复燃;磺胺甲氧嗪(SMP)1克单次治疗6例,5例复燃;乙胺嘧啶50毫克加SMP 1克单次治疗6例,4例复燃;乙胺嘧啶13毫克
The author of 1969 ~ 1970 in Myanmar for chloroquine-resistant falciparum malaria clinical validation. The test subjects are all patients with disease, test methods and resistance grading according to the provisions of the World Health Organization. The test cases were used for determination of urinary chloroquine, and in some cases plasma concentrations of chloroquine were determined. A total of 105 cases were investigated, RI 66 cases, R Ⅱ 19 cases, R Ⅲ 3 cases, 17 cases of sensitive. Where isolated anti-chloroquine cases were randomly divided into 10 groups, each vote with different drugs or compound treatment, if still ineffective, and finally to quinine treatment. The trial found that chloroquine resistant cases of certain other drugs or compounds to varying degrees of tolerance: pyrimethamine 50 mg single treatment in 6 cases, were resumed in 7 to 28 days; sulfamerazine (SMP) 1 G single treatment in 6 cases, 5 cases rekind; pyrimethamine 50 mg plus SMP 1 g single treatment in 6 cases, 4 cases of rekindle; pyrimethamine 13 mg